-
Article
Open AccessSafety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhib...
-
Article
Évaluation d’un programme de formation à la communication dans le cadre d’essais thérapeutiques de phase I selon l’expérience des oncologues
Cette étude réalisée dans un contexte d’essais thérapeutiques de phase I évalue l’impact d’un programme de formation à la communication selon l’expérience des oncologues. Une évaluation de la satisfaction et d...
-
Article
Open AccessRadiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer
Radiotherapy has a critical role in the treatment of small-cell lung cancer (SCLC). The effectiveness of radiation in SCLC remains limited as resistance results from defects in apoptosis. In the current study,...
-
Article
Congrès Targeted Anticancer Therapies — TAT 2014
Les actualités majeures des thérapies ciblées antitumorales se sont discutées lors de la dernière édition du congrès TAT (Targeted Anticancer Therapies) à Washington du 5 au 7 mars 2014. Après l’introduction d...
-
Article
Apport de l’imagerie dans l’évaluation des masses et métastases cardiaques
Les tumeurs cardiaques bénignes et malignes sont rares. L’imagerie en général et l’échographie cardiaque en particulier ont une place centrale dans le diagnostic positif et différentiel, l’évaluation du retent...
-
Article
Low skeletal muscle is associated with toxicity in patients included in phase I trials
Background Low muscle mass has been associated with chemotherapy toxicity. We conducted this prospective study to evaluate the effects of body composition on the occurrence of toxicity in...
-
Article
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
Excision repair cross-complementation group 1 (ERCC1) is a DNA repair enzyme that is frequently defective in non-small cell lung cancer (NSCLC). Although low ERCC1 expression correlates with platinum sensitivi...
-
Article
Erratum: hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Correction to: Oncogene (2006) 25, 4505–4514; doi:10.1038/sj.onc.1209487; published online 17 April 2006 Errors were inadvertently included in Figure 3a of the article mentioned above. In particular, represent...
-
Article
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
Background ES-285 (spisulosine) is a novel compound derived from the marine mollusk Spisula polynoma with evidence of preclinical antitumor activity. This phase I clinical trial was designed to i...
-
Article
Open AccessPrediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
Selecting patients with ‘sufficient life expectancy’ for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ⩾2 of the fol...
-
Article
Open AccessDetection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer
Circulating tumour cells (CTC) have a crucial role in metastasis formation and can consistently provide information on patient prognosis. Epithelial-mesenchymal transition (EMT) is considered as an essential p...
-
Article
Open AccessA direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance o...
-
Article
Les essais précoces
-
Chapter
Cancer broncho-pulmonaire chez le non-fumeur
L’incidence du cancer pulmonaire est incontestablement corrélée au tabagisme, qui est le facteur de risque principal de cette pathologie. Il est estimé que près de 85 % des cas sont dus à l’inhalation de la fu...
-
Article
Soins spécifiques, soins de support — même combat !
-
Article
Open AccessA phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients...
-
Article
Open AccessBMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
Non-small-cell lung cancer (NSCLC) is an aggressive disease in which vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are implicated in tumour growth, tumour resistance to radiation ...
-
Article
Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapati...
-
Article
Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal ...
-
Article
Les inhibiteurs de mTOR
Le déséquilibre entre survie cellulaire et mort cellulaire est une des altérations-clés du processus d'oncogenèse. Parmi les différentes voies favorisant la survie cellulaire, on trouve la voie PI3Kinase-AKT-m...
